News | May 16, 2025
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Tatva Chintan Pharma Chem receives export order worth $35, 55,000
Subscribe To Our Newsletter & Stay Updated
